Atara Biotherapeutics Inc. (ATRA) 63.79 $ATRA Nasdaq

New Post Public Reply Private Reply Replies (0) Message Board

Apr 22, 2015 at 7:06 PM

Atara Biotherapeutics Inc. (ATRA) 63.79 $ATRA

Nasdaq stocks posting largest percentage increases
AP - 52 mins ago
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
AMSC: 10.40 (+1.20), ATRA: 63.79 (+7.64), VASC: 33.30 (+4.06), PKT: 11.42 (+1.91), ASML: 107.81 (+10.06), DWCH: 7.59 (+0.77), MIFI: 6.51 (+0.60), SURG: 5.11 (+0.49)

EBV-CTL Clinical Trial Data Presented by Atara Biotherapeutics' Collaborating Investigators at a Plenary Session at the American Association for Cancer Research Annual Meeting 2015
GlobeNewswire - Mon Apr 20, 5:30AM CDT
Atara Biotherapeutics, Inc. (Nasdaq:ATRA) today announced that its collaborating investigators at Memorial Sloan Kettering Cancer Center (MSK) presented data on its investigational cytotoxic T lymphocytes activated against Epstein-Barr Virus (EBV-CTL) at a Clinical Trials Plenary Session at the 2015 American Association for Cancer Research Annual Meeting (AACR). Clinical data from two clinical studies evaluating the safety and efficacy of EBV-CTL in the treatment of patients with EBV-associated lymphoproliferative disease (EBV-LPD) after allogeneic hematopoietic cell transplantation (HCT) was presented. Under Atara's exclusive option agreement with MSK, Atara has the right to license the exclusive, worldwide rights to three clinical stage T-cell programs, including EBV-CTL. EBV-LPD is a serious malignancy with an unmet medical need that occurs after HCT and in other patients with immune deficiencies. The U.S. Food and Drug Administration (FDA) recently granted breakthrough therapy designation for EBV-CTL based on the data from the two studies.
ATRA: 63.79 (+7.64)

Atara Biotherapeutics' Collaborating Investigators' Abstract on T-Cell Therapy for EBV Lymphoma to be Presented at a Clinical Trials Plenary Session at the American Association for Cancer Research Annual Meeting 2015 is Now Available
GlobeNewswire - Sun Apr 19, 7:30AM CDT
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), today announced that the abstract on cytotoxic T lymphocytes activated against Epstein-Barr Virus (EBV-CTL) that will be presented by its collaborating investigators at Memorial Sloan Kettering Cancer Center (MSK) at a Clinical Trials Plenary Session at the American Association for Cancer Research Annual Meeting (AACR) 2015 is now available. Clinical data on both the safety and efficacy of EBV-CTL in the treatment of patients with rituximab-refractory, EBV-associated lymphoproliferative disease (EBV-LPD) after allogeneic hematopoietic cell transplantation (HCT) will be presented. EBV-LPD is a serious malignancy with an unmet medical need that occurs after HCT and in other patients with immune deficiencies. The U.S. Food and Drug Administration (FDA) recently granted breakthrough therapy designation for EBV-CTL based on the data from the two studies. The AACR annual meeting is being held in Philadelphia, Pennsylvania from April 18th to April 22nd, 2015.
ATRA: 63.79 (+7.64)

The Top 5 Best IPO Performers in the Last Year
at The Street - Thu Apr 16, 2:56PM CDT
These are the top five best IPO performers in the last 12 months.
RDUS: 41.90 (-0.48), KITE: 57.56 (-1.43), CYBR: 65.53 (-0.84), ONCE: 64.79 (-0.25), ATRA: 63.79 (+7.64)

Mr. Klarman bullish on Atara Bio
Seeking Alpha - at Seeking Alpha - Thu Apr 16, 12:56PM CDT

ATRA: 63.79 (+7.64)

Baupost Ups Stake In Atara Biotherapeutics To 19.5%
ValueWalk - Seeking Alpha - Wed Apr 15, 10:32AM CDT
By Marie Cabural Seth Klarman’s Baupost Group increased its stake in Atara Biotherapeutics (NASDAQ: ATRA ) based on its latest 13G filing with the Securities and Exchange Commission (SEC). Based on the filing, Baupost Group...
ATRA: 63.79 (+7.64)

Atara Biotherapeutics, Inc. to Present at the 2015 Jefferies Immuno-Oncology Summit
GlobeNewswire - Mon Apr 13, 5:34AM CDT
Atara Biotherapeutics, Inc. (Nasdaq:ATRA) today announced that Isaac Ciechanover, M.D., the company's Chief Executive Officer, will present at the 2015 Jefferies Immuno-Oncology Summit on Wednesday, April 15, 2015 at 11:00 am EDT in Boston.
ATRA: 63.79 (+7.64)

Atara Biotherapeutics, Inc. to Present at the Needham Healthcare Conference
GlobeNewswire - Thu Apr 09, 5:30AM CDT
Atara Biotherapeutics, Inc. (Nasdaq:ATRA) today announced that Gad Soffer, the company's Chief Operating Officer, will present at the 2015 Needham Healthcare Conference on Tuesday, April 14, 2015 at 5:00 pm EDT in New York City.
ATRA: 63.79 (+7.64)

Week Ahead: Is GoDaddy The Master Of Its Domains? Up To 4 IPOs This Week
Renaissance Capital IPO Research - Seeking Alpha - Mon Mar 30, 6:26AM CDT
The IPO market should end the first quarter with a bang as GoDaddy (Pending: GDDY ) goes public during the shortened holiday week. GoDaddy to go public GoDaddy aims to raise $396 million at a market cap of $3 billion, or an enterprise value of...
WOWO: 8.41 (-0.88), KRNT: 14.99 (unch), VIRT: 21.81 (-0.54), TANH: 11.82 (+0.40), PRTY: 20.65 (-0.22), VRAY: (), VLRX: (), ATRA: 63.79 (+7.64), FGEN: 26.46 (-1.37), GDDY: 24.77 (-0.01)

Atara Biotherapeutics, Inc. Appoints Eric Dobmeier, Chief Operating Officer of Seattle Genetics, Inc., to Its Board of Directors
GlobeNewswire - Fri Mar 27, 5:30AM CDT
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing innovative therapies for patients with debilitating diseases, today announced that Eric Dobmeier has joined its Board of Directors.
SGEN: 36.92 (-0.32), ATRA: 63.79 (+7.64), STML: 16.51 (+0.13)

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Mar 25, 11:45AM CDT

TANH: 11.82 (+0.40), CCSC: 5.36 (-0.04), STMP: 67.03 (-1.07), HGSH: 3.10 (-0.06), FSNN: 4.38 (+0.12), ATRA: 63.79 (+7.64), KRFT: 88.25 (-0.22), LPTN: 2.26 (unch), IIJI: 8.62 (-0.04), KFX: 11.02 (-0.01), ESPR: 100.53 (-2.60), FCSC: 4.01 (+0.01), ORMP: 7.25 (-0.10), AFMD: 7.94 (+0.11), SEED: 1.66 (+0.05), CALA: 12.93 (-1.06), LIME: 2.85 (-0.12), VBLT: 4.37 (-0.08), APOL: 17.64 (+0.11), REPH: 10.71 (-0.78)

Atara Biotherapeutics' Collaborating Investigators to Present Clinical Data on T-Cell Therapy for EBV Lymphoma at a Clinical Trials Plenary Session at the American Association for Cancer Research Annual Meeting 2015
GlobeNewswire - Thu Mar 19, 5:30AM CDT
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), today announced that its collaborating investigators at Memorial Sloan Kettering Cancer Center (MSK) will present clinical data from two studies of cytotoxic T lymphocytes activated against Epstein-Barr Virus (EBV-CTL) at a Clinical Trials Plenary Session at the American Association for Cancer Research Annual Meeting (AACR) 2015. Clinical data on both the safety and efficacy of EBV-CTL in the treatment of patients with rituximab-refractory, EBV-associated lymphoproliferative disease (EBV-LPD) after allogeneic hematopoietic cell transplantation (HCT) will be presented. EBV-LPD is a serious malignancy with an unmet medical need that occurs after HCT and in other patients with immune deficiencies. The U.S. Food and Drug Administration (FDA) recently granted breakthrough therapy designation for EBV-CTL based on the data from the two studies. The AACR annual meeting will be held in Philadelphia, Pennsylvania April 18th-22nd, 2015.
ATRA: 63.79 (+7.64)

FDA Designates New Treatment that Destroys EBV Expressing Cells as 'Breakthrough'; The Center for the Biology of Chronic Disease (CBCD) Reviews a Report
PRWeb - Thu Mar 12, 11:01PM CDT
"Infected with the Epstein Barr Virus (EBV)? The Center for the Biology of Chronic Disease (CBCD), which tested the formula of Novirin in two post-marketing clinical studies, recommends taking this natural antiviral supplement." - Greg Bennett, CBCD
ATRA: 63.79 (+7.64)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Lyon Biennale 2026: Art, Dreams, and Lyon's Magic

Unveiling the Art Spectacle in Lyon Alright, buckle up folks, because the 18th Lyon Biennale – Contemporary Art is about to take the stage in grand fashion. Starting on the 19th of September, this art fiesta is not just any exhibit; it's an eleven-venue citywide takeover that runs until the 13th of December, and it is poised to shake up the art scene like a good splash...

Cultural Convergence: Ordos Event Captivates Global Visitors

Ordos: Where Cultures Connect Seamlessly Spanning continents and cultures, the recent 'Warm City' event in Ordos, Inner Mongolia, drew international attention like bees to honey. Now, if you're thinking this is just another cultural shindig, think again. François Tchiegue, an ambassador of China-Africa cultural exchanges, described it best when he noted how the morin...

$Aluminum Refractory Market to Hit $2.73B by 2031$

Riding the Aluminum Refractory Wave to 2031 Look, when you want to throw some cash in a market that's gaining steam, aluminum refractory materials might not be your first pick. But here's the thing: it's charging ahead to a cool $2.73 billion by 2031. And if you're keeping tabs on the likes of RHI Magnesita and Calderys, this is a sector that deserves a once-over. What...

Thermoplastic Polyimide: A $0.86 Billion Market by 2032

It's not often you get hyped about a compound with a name like 'thermoplastic polyimide,' but hold your horses—this isn't just any chemical. If you're watching markets with a sharp eye, you’ll see this thing estimated at $0.56 billion in 2026, gunning for a hefty $0.86 billion by 2032. We're talking about a solid 7.4% CAGR ride here folks, according to new data from...

Six Flags Offers Flexible Payment Plan with Flex Pay

New Payment Option Brings Flexibility Seems like Six Flags isn't just about roller coasters anymore—now they're playing the long game with wallet-friendly options. Flex Pay by Upgrade is the latest spin on season pass financing, letting guests divvy up payments and kickstart their amusement park fun right away. This move could be a game-changer for folks looking to lock...

Advenica: Rising Star in Secure File Transfer Market

Advenica's Ascent in Secure File Transfer The cybersecurity world never sleeps, and with the rapid pace of digital threats, it's no surprise that secure file transfer solutions are becoming hotter commodities than coffee pots on Wall Street. Advenica, a name that might not ring a bell for everyone, has emerged as an 'Emerging Leader' in MarketsandMarkets' latest...

WaFd and EverBank $3.9B Deal Spurs Big Bank Shift

Remember the good old days when banking was just about collecting interest? Now it's all about combining forces to bolster strength, and that's just what we're seeing with WaFd, Inc. (NASDAQ: WAFD) and EverBank Financial Corp flipping the script and shaking hands on a $3.9 billion reverse merger. Strategic Vision: A New Chapter They're calling it a 'strategic...

CalExitNow Fights Federal Interference in CA Elections

California's Election Integrity: A Ticking Time Bomb Strap in for a bumpy ride, folks—California might soon find its electoral process caught in a Washington whirlwind. CalExitNow, the group advocating for California's independence, is sounding alarms about looming federal interventions that could shake the state's democratic foundations. The Federal Storm Rolling In...

Universal Music Wraps €250M Share Buyback Plan

Universal's Encore Performance in the Markets Universal Music Group (EURONEXT: UMG), the behemoth in music-based entertainment, just wrapped up its €250 million share buyback program. Talk about a grand finale! In a week’s worth of maneuvering from August 31 to September 4, they snagged 294,340 of their own shares, all for the pretty price of €14.65 a pop. Grand...

CDTL's E-Drive and EMB Shape Future of Automation

A Bumpy Ride Towards Future of Commercial Vehicles In the midst of a bustling Hannover, CDTL, that plucky contender in e-drive systems, is making noise at IAA Transportation 2026. Now, if there's one thing I've learned watching this circus we call the auto industry, it's that innovation rarely strolls in with a polite knock. It barges through the door, often leaving a...